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Abstract 
Several methods are used to counter the deadly disease 
cancer. Zinc oxide nanoparticles (ZnO NPs) is one of the 
metal oxide nanoparticles which had been used in anti-
cancer activities due to its large bandwidth and high 
exciting binding energy and it has potential applications 
like antibacterial, antifungal, anti-diabetic, anti-
inflammatory, wound healing, antioxidant, optic 
properties and also which holds promise to treat cancer 
effectively. Studies have shown that Zinc metal oxide 
nano particles induce cytotoxicity in cancer cells. The 
mechanism for antitumor could work through apoptosis 
or the generation of reactive oxygen species or through 
necrosis and among other possibilities. This review is on 
some of the most significant antitumor results obtained 
with zinc oxide nanoparticles depending on their size, 
surface morphology, methods of preparation and also its 
cytotoxicity result.  
Keywords: Anti-cancer activity, ZnO nanoparticles, Cancer cell-
lines, cytotoxicity 
1. Introduction  
Cancer is known as one of the most deadly diseases for 
humankind. According to the NCI Dictionary of Cancer Terms, 
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cancer is a term for diseases in which abnormal cells divide without 
control and can invade nearby tissues. Cancer cells can also spread 
to other parts of the body through the blood and lymph systems. 
There are several main types of cancer. Carcinoma is a cancer that 
begins in the skin or in tissues that line or cover internal organs. 
Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood 
vessels, or other connective or supportive tissue. Leukemia is a 
cancer that starts in blood-forming tissue, such as the bone marrow, 
and causes large numbers of abnormal blood cells to be produced 
and enter the blood. Lymphoma and multiple myeloma are cancers 
that begin in the cells of the immune system. Central nervous 
system cancers are cancers that begin in the tissues of the brain and 
spinal cord. Cancer is also called malignancy. Several methods and 
ways are implemented to eliminate this disease.  
Recently, nanoparticles (NPs) have much attention due to their use 
in cancer therapy. Studies have shown that different metal oxide 
nanoparticles induce cytotoxicity in cancer cells, but not in normal 
cells. In some cases, such anticancer activity has been demonstrated 
to hold for the nanoparticle alone or in combination with different 
therapies.[1] Nanomedicine is the current field for biomedical 
applications, involves engineered nanoparticles to treat the cancer 
disease and also contains advanced imaging and therapeutic 
capabilities, for early detection and treatment of various cancer 
with potentiality.[2] Nanoparticles shows unique properties, so its 
a preferable choice to replace the conventional treatment. These 
have biocompatible, active targeting and also passive targeting, 
and multifunctionality solubility and bioavailability compare to 
traditional cancer treatments.[3] Nanoparticles bind the drugs and 
encapsulate drugs to the surface due to their high surface to 
volume ratio. This leads to higher therapeutic load on to the target 
and less side effects to the normal cell. The sizes of the 
nanoparticles are comparable to the biomolecules so they can 
mimic and hack the activity of biomolecules. Hence, the localized 
body system, by modification of the surface leads to enhance the 
small size and also solubility.[2, 3] Nanoparticles as a 
nanomedicine are now personilized medicines.[4] Several 
nanoparticles like cerium oxide nanoparticles, Au NPs, Ag NPS, 





CuO NPS, ZnO NPs are also used for cancer treatments. The 
efficacy, the selectivity and the potency in cancer therapy towards 
the cancer cells show promising result. They show cytotoxicity by 
zinc-dependent protein activity disequilibrium and ROS 
induction.[5] This review aims to find the unique properties of ZnO 
NPs as their role in the selective cytotoxicity to some cancer cell 
lines of the human body and its dependent of size and shape, and 
Inhibitory Concentration (IC50) values. 
2. ZnO Nanoparticles 
The ZnO NPs have received much attention for their applications 
in cancer therapy. In the group of metal oxides, ZnO NPs are 
significant for their characterized photocatalytic and photo-
oxidizing ability against chemical and biological species. The ZnO 
nanoparticles are nano-sized particles of ZnO with a size less than 
100 nm. They can be prepared by several different methods, such as 
solid, liquid (i. e., chemical) and gaseous. There are a variety of 
chemical methods, for example mechanochemical process, 
precipitation process, precipitation in the presence of surfactant, 
sol-gel method, solvo-thermal, hydrothermal, emulsion and micro-
emulsion methods.[6] Surfactant, polymer molecules, or, Triton-X 
100 or PEG are used as a stabilising agents. The main significance 
of nanoparticles is that the size reduction to nanoscale that leads to 
the development of new unique physicochemical, structural, 
electronic and magnetic properties of nanoparticles, which are not 
present in their macro or bulkier form.[7] A variety of ZnO 
nanostructures have been synthesized, including nanoparticles, 
nanowires, nanorods, nanotubes, nanobelts and other complex 
morphologies. They have wide range of applications in cancer 
therapy, biosensing, drug/gene delivery, nanomachines that can 
act as biological mimetic, biomaterials for tissue engineering, shape 
memory polymers such as molecular switches, etc.[8] 
Nowadays, ZnO NPs have drawn attention for their effectiveness 
in cancer therapy.[6] Studies have shown that ZnO NPs induce 
cytotoxicity selectively in a cell-specific and proliferation-
dependent manner.[9–11] The cytotoxicity of ZnO NPs toward 





mammalian cells, and other types of cells are to be considered. The 
anticancer activity of ZnO NPs, mechanisms of apoptosis in cancer 
cells due to ZnO NP treatment, etc. are still to be worked. 
The nanoparticles of zinc oxide were synthesized by the facile 
precipitation method with starch as the nontoxic capping agent. 
The average crystallite size was estimated from the peak width at 
half maximum using Scherer formula and the calculated crystallites 
size is 32.7 nm. To further support the formation mechanism of 
ZnO NPs, FTIR studies were performed. The fundamental mode of 
vibration at 3404.13 cm-1 corresponds to the O-H stretching 
vibration due to the water molecule present in the sample. The 
peaks at 2928.23 cm-1 and 1007.06 cm-1 are due to the presence of C-
O and C-H stretching vibrations indicating the saccharide 
strucuture of starch. The peak at 759.92 cm-1 is attributed to the C-O 
bond stretching. The band at 1415.77 cm-1 and 1644.52 cm-1 
correspond to the C=O asymmetric and the C=O symmetric 
stretching vibration. The prominent peaks at 702.33 cm-1 and 521.57 
cm-1 indicate the stretching vibrations of ZnO nanoparticle.  
 
Figure 1. Pictorial representation of cytotoxicity of ZnO NPs on different cancer cells 
The average crystallite size is 32.7 nm having rice like morphology. 
The MTT assay is used to for synthesized ZnO NPs, have been 
tested for their efficacy of cytotoxic activity against MCF-7 (breast 
cancer cells). The cell viability evaluated after 24 h exposure to ZnO 
NPs of various concentrations ranging from (10 μg/ml- 200 
μg/ml). The ZnO NPs induced cytotoxicity on MCF-7 cell lines was 
found to be increasing with an increase in concentration of ZnO 
NPs. The 50% viability happens at the concentration of 40 μg/ml 
which is the half maximal. The IC50 and the metabolic activity are 





characteristic, which decrease with the decreasing of the dose of 
ZnO NPs incubated with the MCF-7cells.[12] 
The zinc oxide NPs were used at a very low concentration and 
were found to exhibit activity against HepG2 (liver cancer) and 
MCF-7 (breast cancer) cancer cells in a dose-dependent manner: 
viability, measured by the MTT assay, showed a dose-dependent 
decrease. At a very low concentration such as 25 μg/ml the cell 
viability was less than 10% in the case of HepG2 cells. The results of 
emphasis on the anti-proliferative studies clearly demonstrate that 
treatments with NPs sensitize cancer cells. The degree of apoptosis 
was found to be enhanced with an increase in the concentration of 
NPs, and a significant concentration of NPs resulted in cell death in 
both cancer cell lines.[13] In that study, quantitative real-time PCR 
was utilized to analyze the mRNA levels of apoptotic markers (p53, 
Bax, bcl-2 and caspase-3) in HepG2 cells exposed to ZnO NPs at a 
concentration of 50 μg/ml for 24 h. The results showed that the 
mRNA levels of these apoptotic markers were significantly altered 
in HepG2 cells due to ZnO NP exposure. The mRNA level of the 
tumor suppression gene p53 was 1.9-fold higher and the mRNA 
expression levels of the pro-apoptotic gene Bax and the anti-
apoptotic gene bcl-2 were decreased (2.7- and 2.5-fold, respectively) 
in the exposed cells, compared to untreated cells. Moreover, the 
effect of ZnO NPs on the mRNA expression level of caspase-3 was 
studied and was found to be 1.8-fold higher in the treated cells than 
the untreated control cells. The mRNA expression levels of p53, 
Bax, bcl-2 and caspase in HepG2 cells in response to ZnO NP 
exposure were studied because apoptosis is controlled through 
these pathways. The quantitative real-time PCR results show that 
ZnO NPs up-regulate the mRNA levels of the cell cycle checkpoint 
protein p53 and the pro-apoptotic protein Bax. The expression of 
the anti-apoptotic protein bcl-2 was down-regulated in cells 
exposed to ZnO NPs. Furthermore, the up-regulation of p53 and 
the down-regulation of bcl-2 family members, such as Bax, induce 
the permeabilization of the outer mitochondrial membrane, which 
releases soluble proteins from the intermembrane space into the 
cytosol, where they promote caspase activation.[14] 





Wahab et al. have synthesized ZnO nanoparticle with the average 
size of approximately 10 nm, characterized, studied morphology 
and their induction of oxidative stress in Cloudman S91 melanoma 
cancer cells was studied.[15] Various doses of ZnO nanoparticles 
were treated with melanoma cancer cells for 24 h of incubation at 
37oC. MTT assay was done for the cell viability whereas the 
morphology of the cells was observed via confocal laser scanning 
microscopy (CLSM), which revealed that when the time interval 
was increased, the number of cells decreased. The apoptosis-
correlated, intracellular production of reactive oxygen species 
(ROS) was also measured with melanoma cancer cells with varying 
ZnO nanoparticle doses. After pre-incubation with ZnO N Ps in 
concentrations of 0.002-20 μg/ml, the HNSCC cell lines HLaC 78 
and UD-SCC 7A as well as primary oral mucosa cells (pOMCs) 
were treated with UVA-1. Cell survival and viability was observed 
by 3-(4, 5-dimethylthiazol-2-yl)-2,5- diphenyl-tetrazoliumbromide-
(MTT)-assay and fluorescein diacetate test. Apoptosis was assessed 
by annexin-V propidium iodide flow cytometry. Intranuclear 
distribution of the rod-shaped particles was observed in 3.5% of 
head and neck squamous cell carcinoma cell lines (HNSCC) and in 
0.5% of pOMCs. UVA-1 irradiation for 15 min in combination with 
0.2 and 2 μg/ml of ZnO NP dispersion was shown to reduce the 
viability of cancer cell lines significantly in comparison to cells 
without NP exposure or UVA-1 treatment only. For HLaC 78, a 
significant reduction in viable cells was seen at 10 min of UVA-1 
treatment and a ZnO NP concentration of 2 μg/ml. For HLaC 78, a 
significant reduction in viable cells was seen at 10 min of UVA-1 
treatment and a ZnO NP concentration of 2 μg/ml. Flow cytometry 
indicated that cell death occurred primarily through necrosis. In 
pOMCs, vitality was not influenced either by UVA-1 treatment 
orZnO NP exposure up to 2 μg/ml or a combination of both.ZnO 
NPs showed cytotoxicity at 20 μg/ml without UVA-1. Due to their 
photocatalytic properties, ZnO NPs may induce cell death in 
human HNSCC cell lines in vitro. Further studies will evaluate a 
possible benefit in adjuvant cancer therapy [15]. Hackenbert et al. 
synthesized ZnO NP of particle size 74nm pre-incubation followed 
by UVA-1 irradiation induced a significant reduction in viable 
HNSCC in vitro [16]. 





Therapeutic cancer vaccines are emerging as part of an anticancer 
regimen that utilizes specific antigens to initiate and modulate the 
antitumor immune response.[17] Dendritic cells (DCs) have been 
used for therapeutic cancer vaccines.[18] DC-based cancer 
immunotherapy that destroys tumors requires a clinically-suitable 
delivery system for the target antigens in the DCs. In one study, the 
authors developed iron oxide (Fe3O4)-zinc oxide (ZnO) core-shell 
NPs (CSNPs) to have ZnO-binding peptides to carry tumor 
antigens in DCs. This NP-antigen complex was efficiently taken up 
by the DCs and was demonstrated to function as a cancer 
immunotherapy via injection of the DCs containing the CSNP-
antigen complex into the hind footpads of mice. Mice immunized 
with DCs containing the NP-antigen complex showed enhanced 
tumor antigen-specific T-cell responses, delayed tumour growth 
and better survival than controls.[19] However, a study of the 
potential toxicity of these new nanocarriers is required. Recently, a 
repeated toxicity study was performed in vivo by subcutaneous 
injection in mice and showed a dose-dependent increase in 
granulomatous inflammation at the injection site of the CSNP-
treated animals. But no alterations in the body and other 
histopathological lesions in other organs could be attributed to the 
CSNPs.[20] 
In another study, highly pure ZnO nanoparticles with a narrow 
size distribution of 16-19 nm prepared by the simple DMC (Dry 
Mechano-Chemical) method are considered. The anticancer activity 
on MCF-7 (Breast cancer cell) and A549 (Lung Cancer cell) were 
determined by the MTT (Methylthiazolydiphenyl-tetrazolium 
bromide) assay. A549 and MCF-7 cells were exposed to ZnO-NPs 
and they exhibited 50% reduction at a very low concentration 31.2 
μg/ml. Thus, the reduction in cell viability with NPs induces 
cytotoxicity in cancerous cells. There is a size dependent 
effectiveness of ZnO nanoparticles in the removal of cancer cells 
and also a positive correlation with reduced toxicity. ZnO 
nanoparticles with an average size between 16 to 19 nm and sphere 
shapes were successfully synthesized using dry grinding method. 
The synthesis method reported here is easily scalable for large scale 
production, economically feasible, biocompatible and cost effective. 





The results suggest that with the aid of oxide based nanoparticles 
conditional chemotherapeutic agents may have even broader range 
of applications in the treatment of cancer cells. The dosage 
particles’ size-dependent activity against cancer cells and the 
variation in toxicity need to be further investigated to establish 
optimum standards.[21] 
3. Conclusion 
This review is on ZnO nanoparticles. Zinc oxide NPs’ role in the 
human body as anti-cancer agent depends on the size, dosage, the 
surface morphology and IC50 value. The probable mechanism 
surrounding ZnO NPs with the biology of the human body, leads 
to its selective localization and cytotoxicity towards cancer cells. 
While ZnO NPs induce cytotoxicity towards cancer cells through 
oxidative stress via ROS generation, the response of zinc-mediated 
protein activity disequilibrium as a result of high levels of 
intracellular zinc ions is a more likely cause. There is in vivo 
research into nanoparticles for design of NPs for their better clinical 
use. A society-oriented collaboration leads to the development of 
smart nanoparticles with accurcy of selectivity and toxicity towards 
cancer cells with biocompatibility. 
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